Tiankang Biotech announced that the company plans to terminate the “300,000 Piglet Breeding and 200,000 Pig Fattening Base Construction Project”, a non-public stock raising project. The project originally intended to raise 430 million yuan, and the remaining capital raised as of July 31, 2026 was 324 million yuan. The reason for the termination was that pig prices continued to be sluggish, making it difficult to meet expectations for continued implementation. The remaining funds raised will permanently supplement working capital for daily production and operation. The matter has been reviewed and approved by the company's board of directors and still needs to be submitted to the shareholders' meeting for consideration. The sponsor, CITIC Construction Investment Securities, has no objection to the matter.

Tiankang Biotech announced that the company plans to terminate the “300,000 Piglet Breeding and 200,000 Pig Fattening Base Construction Project”, a non-public stock raising project. The project originally intended to raise 430 million yuan, and the remaining capital raised as of July 31, 2026 was 324 million yuan. The reason for the termination was that pig prices continued to be sluggish, making it difficult to meet expectations for continued implementation. The remaining funds raised will permanently supplement working capital for daily production and operation. The matter has been reviewed and approved by the company's board of directors and still needs to be submitted to the shareholders' meeting for consideration. The sponsor, CITIC Construction Investment Securities, has no objection to the matter.